News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
The Bulk Drug Park is expected to attract investment of around Rs. 10,000 crore and provide employment to more than 20,000 people
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Subscribe To Our Newsletter & Stay Updated
